EyePoint, Inc. (EYPT)
4.78
+0.20
(+4.37%)
USD |
NASDAQ |
Sep 02, 16:00
4.75
-0.03
(-0.63%)
After-Hours: 20:00
EyePoint Research and Development Expense (TTM) : 262.73M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 262.73M |
| March 31, 2026 | 234.61M |
| December 31, 2025 | 221.04M |
| September 30, 2025 | 205.20M |
| June 30, 2025 | 186.99M |
| March 31, 2025 | 161.31M |
| December 31, 2024 | 132.88M |
| September 30, 2024 | 107.45M |
| June 30, 2024 | 95.28M |
| March 31, 2024 | 81.18M |
| December 31, 2023 | 64.66M |
| September 30, 2023 | 62.25M |
| June 30, 2023 | 56.05M |
| March 31, 2023 | 53.32M |
| December 31, 2022 | 49.64M |
| September 30, 2022 | 43.02M |
| June 30, 2022 | 40.35M |
| March 31, 2022 | 32.97M |
| December 31, 2021 | 28.50M |
| September 30, 2021 | 24.79M |
| June 30, 2021 | 20.38M |
| March 31, 2021 | 18.05M |
| December 31, 2020 | 17.42M |
| September 30, 2020 | 16.35M |
| June 30, 2020 | 15.74M |
| Date | Value |
|---|---|
| March 31, 2020 | 16.42M |
| December 31, 2019 | 15.37M |
| September 30, 2019 | 15.42M |
| June 30, 2019 | 18.16M |
| March 31, 2019 | 18.97M |
| December 31, 2018 | 18.50M |
| September 30, 2018 | 18.54M |
| June 30, 2018 | 15.63M |
| March 31, 2018 | 14.03M |
| June 30, 2017 | 14.88M |
| March 31, 2017 | 14.77M |
| December 31, 2016 | 14.56M |
| September 30, 2016 | 14.93M |
| June 30, 2016 | 14.06M |
| March 31, 2016 | 12.93M |
| December 31, 2015 | 13.16M |
| September 30, 2015 | 12.39M |
| June 30, 2015 | 11.86M |
| March 31, 2015 | 11.20M |
| December 31, 2014 | 10.13M |
| September 30, 2014 | 9.853M |
| June 30, 2014 | 9.573M |
| March 31, 2014 | 9.587M |
| December 31, 2013 | 8.905M |
| September 30, 2013 | 7.986M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ocular Therapeutix, Inc. | 223.51M |
| Eli Lilly & Co. | 14.60B |
| Elanco Animal Health, Inc. | 371.00M |
| Amylyx Pharmaceuticals, Inc. | 92.08M |
| Nuvation Bio, Inc. | 128.85M |